Approval · Notice of Compliance 16902 · 2015
AURO-RIZATRIPTAN: Notice of Compliance 16902
Issued May 13, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16902
- Date
- May 13, 2015
- Company
- Auro Pharma Inc.Woodbridge, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5-ht1 receptor agonist / migraine therapy
- Canadian reference product
- MAXALT (Merck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AURO-RIZATRIPTAN | 02441144 | Dormant |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 10 MG per TAB